Novartis announced patients with myelofibrosis initially randomized to...
In two Phase III studies, Jakavi ® reduced the risk of death and maintained spleen reductions at three years compared to conventional therapy and placebo Similar survival benefit seen in patients with...
View ArticleNovartis: CHMP of the European Medicines Agency adopted a positive opinion...
Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack[1] Clinical data show Jakavi® (ruxolitinib)...
View ArticleNovartis announced patients with myelofibrosis initially randomized to...
In two Phase III studies, Jakavi ® reduced the risk of death and maintained spleen reductions at three years compared to conventional therapy and placebo Similar survival benefit seen in patients with...
View ArticleNovartis: CHMP of the European Medicines Agency adopted a positive opinion...
Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack[1] Clinical data show Jakavi® (ruxolitinib)...
View ArticleNovartis announced patients with myelofibrosis initially randomized to...
In two Phase III studies, Jakavi ® reduced the risk of death and maintained spleen reductions at three years compared to conventional therapy and placebo Similar survival benefit seen in patients with...
View ArticleNovartis: CHMP of the European Medicines Agency adopted a positive opinion...
Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack[1] Clinical data show Jakavi® (ruxolitinib)...
View Article
